Interleukin-8 is not a predictive biomarker for the development of the acute promyelocytic leukemia differentiation syndrome

Autor(es)

de Almeida, Luciana Yamamoto ^{[1, 2]} ; Pereira-Martins, Diego Antonio ^{[1, 2]} ; Gouvea Lima, Ana Silvia ^[1] ; Baggio, Marcia Sueli ^[3] ; de Araujo Koury, Luisa Correa ^[1] ; Lange, Ana Paula ^{[1, 2]} ; Bassi, Sarah Cristina ^[2] ; Scheucher, Priscila Santos ^[1] ; Rego, Eduardo Magalhaes ^{[1, 2, 4]}

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Dept Med Images Hematol & Clin Oncol, Hematol Div, Ribeirao Preto Med Sch, Ribeirao Preto - Brazil

^[2] Univ Sao Paulo, Ctr Cell Based Therapy, Ribeirao Preto Med Sch, Ribeirao Preto - Brazil

^[3] Univ Sao Paulo, Hosp Clin, Hemostasis Lab, Fac Med Ribeirao Preto, Ribeirao Preto - Brazil

^[4] Univ Sao Paulo, Fac Med, LIM31, Hematol Div, Hemoctr, Av Dr Eneas Carvalho Aguiar 155, 1st Floor, BR-05403000 Sao Paulo, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: BMC CANCER; v. 20, n. 1 AUG 28 2020.
• Citações Web of Science: 0

Resumo

Background Differentiation syndrome (DS) is the main life-threatening adverse event that occurs in acute promyelocytic leukemia (APL) patients treated with all-trans retinoic acid (ATRA). Cytokine imbalances have been reported to play role during the developing of acute promyelocytic leukemia differentiation syndrome (APL-DS). However, the relationship between the plasma cytokine levels and their prognostic value for the prediction of DS developing in patients with APL during the treatment with ATRA and anthracyclines has not been previously reported. Methods In this study, we followed an APL cohort (n = 17) over 7 days of ATRA therapy in DS (n = 6) and non-DS groups (n = 11). Interleukin (IL)-1 beta, IL-6, IL-8, IL-10, IL-12p70 and TNF-alpha were measured in the peripheral blood plasma from 17 patients with APL and 11 healthy adult controls by using the cytometric bead array method. Results In non-DS patients, IL-8 plasma levels were significantly reduced in the seventh day of ATRA treatment (34.16; 6.99 to 147.11 pg mL(- 1)in D0 vs. 10.9; 0 to 26.81 pg mL(- 1)in D7;p = 0.02) whereas their levels did not discriminate between DS and non-DS development during the entire induction period (allp > 0.05 in D0, D3, and D7). No significant differences were found in IL-6 levels between groups (p > 0.05 in D0-D7). Other cytokines tested were all undetectable in patients with APL or healthy controls. Conclusions We demonstrated that the modulation of IL-8 following ATRA treatment may occur regardless of the development of DS and, therefore, does not appear to be a predictive biomarker to monitor the APL-DS. (AU)

• Processo FAPESP: 13/08135-2 - CTC - Centro de Terapia Celular
• Beneficiário: Dimas Tadeu Covas
• Modalidade de apoio: Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs
• Processo FAPESP: 16/02713-2 - Efeitos da terapia com erlotinib e gefitinib em associação ao ácido all-trans retinóico e trióxido de arsênico na leucemia promielocítica aguda: estudo in vitro, ex vivo e em modelo experimental murino.
• Beneficiário: Luciana Yamamoto de Almeida
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 17/23117-1 - Avaliação da via TP53/TP73 na enxertia de células de leucemia promielocítica aguda em modelo de xenotransplante
• Beneficiário: Diego Antonio Pereira Martins
• Modalidade de apoio: Bolsas no Brasil - Doutorado